Resumes
Resumes
Elias Quijano Phones & Addresses
-
Durham, CT
-
New Haven, CT
-
Hialeah, FL
Publications
Us Patents
Compositions And Methods For Treating Sickle Cell Disease
View pageUS Patent:
20220280656, Sep 8, 2022
Filed:
Jul 31, 2020
Appl. No.:
17/631661
Inventors:
- New Haven CT, US
Elias Quijano - Durham CT, US
W. Mark Saltzman - New Haven CT, US
Hee Won Suh - New Haven CT, US
Elias Quijano - Durham CT, US
W. Mark Saltzman - New Haven CT, US
Hee Won Suh - New Haven CT, US
International Classification:
A61K 48/00
A61K 9/51
C12N 15/113
A61K 9/51
C12N 15/113
Abstract:
Peptide nucleic acid (PNA) oligomers that target the β-globin gene and can increase the frequency of recombination of donor oligonucleotide at the site of a Sickle Cell Disease mutation are provided. Nanoparticle formulations for delivering the PNA oligomers and donor oligonucleotides, and potentiating agents for increase the frequency of recombination of the donor oligonucleotide are also provided. Methods of using the PNA oligomers, donor oligonucleotides, nanoparticles, and potentiating agents for treating Sickle Cell Disease are also provided.
Compositions For Enhancing Targeted Gene Editing And Methods Of Use Thereof
View pageUS Patent:
20170283830, Oct 5, 2017
Filed:
Feb 16, 2017
Appl. No.:
15/434978
Inventors:
- New Haven CT, US
- Pittsburg PA, US
Raman Bahal - Hamden CT, US
Nicole Ali McNeer - Westport CT, US
Danith H. Ly - Pittsburgh PA, US
Elias Quijano - New Haven CT, US
- Pittsburg PA, US
Raman Bahal - Hamden CT, US
Nicole Ali McNeer - Westport CT, US
Danith H. Ly - Pittsburgh PA, US
Elias Quijano - New Haven CT, US
International Classification:
C12N 15/90
A61K 48/00
A61K 9/16
C12N 15/11
A61K 48/00
A61K 9/16
C12N 15/11
Abstract:
Compositions and methods for enhancing targeted gene editing and methods of use thereof are disclosed. In the most preferred embodiments, gene editing is carried out utilizing a gene editing composition such as triplex-forming oligonucleotides, CRISPR, zinc finger nucleases, TALENS, or others, in combination with a gene modification potentiating agent such as stem cell factor (SCF), a CHK1 or ATR inhibitor, or a combination thereof. A particular preferred gene editing composition is triplex-forming peptide nucleic acids (PNAs) substituted at the γ position for increased DNA binding affinity. Nanoparticle compositions for intracellular delivery of the gene editing composition are also provided and particular advantageous for use with in vivo applications.